- Home
- » Tags
- » Romiplostim
Top View
- Oncology Drug Reference Guide
- Nplate) Reference Number: CP.PHAR.179 Effective Date: 03.01.16 Last Review Date: 02.21 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log
- NPLATE (Romiplostim) for Injection, for Subcutaneous Use ------CONTRAINDICATIONS ------ Initial U.S
- Romiplostim for Severe Thrombocytopenia in the Treatment of Chronic Hepatitis C Virus Infection: a New Option for Clinicians?
- We Know How Hard the First Step Can Be
- Mitigative E Cacy of the Clinical Dosage Administration of Granulocyte
- The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin
- Lumicera Specialty Drug List
- The Thrombopoietin Mimetic Romiplostim Leads to the Complete Rescue of Mice Exposed to Lethal Ionizing Radiation
- Brand Generic Guide
- 07 Poster Viewing I 65..65
- The Role of Eltrombopag and Romiplostim As The
- Romiplostim Promotes Platelet Recovery in a Mouse Model of Multicycle Chemotherapy-Induced Thrombocytopenia Patricia L
- Phc P & T Additions, Changes & Deletions: P & T Committee
- PRESCRIBING INFORMATION After Suspected Or Confirmed Exposure to Myelosuppressive Doses of These Highlights Do Not Include All the Information Needed to Use Radiation
- Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: What’S New?
- List of Drugs That Are Included in the Program
- 129-5-1. Prior Authorization. (A) Any Medical Service May Be Placed by The
- Shareholders 2017 Letter to Shareholders
- Policy: Promacta® (Eltrombopag Tablets) Annual Review Date: 09/17/2020
- C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
- Form 10-K Amgen Inc
- Long-Term Safety and Efficacy of Romiplostim for Treatment of Immune Thrombocytopenia
- Mitigative Efficacy of the Clinical Dosage Administration Of
- Reimbursement Criteria for Frequently Requested Drugs
- Amgen Safety Net Foundation Offers Replacement Product for Physician-Administered Medications
- The Bioanalysis, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Fusion Peptides and Proteins
- Myeloid Cytokines for Treatment of Acute Exposure To
- Specialty Drug List 08-24-10
- Attachment 2. Extract from the Clinical Evaluation Report for Eltrombopag
- Mandatory Specialty Drug List
- Biosimilars: What You Need to Know
- Increasing Platelets Without Transfusion: Is It Time to Introduce Novel Thrombopoietic Agents in Neonatal Care?
- 2018 Letter to Shareholders
- Specialty Drug List
- Nplate, INN-Romiplostim
- Specialty Drug List 10-22-12Final1
- Clinigen Signs Distribution Agreement with Amgen in Territories Across Africa and Asia
- Romiplostim (Nplate ) As an Effective Radiation Countermeasure to Improve Survival and Platelet Recovery in Mice
- View the Specialty Pharmacy 1199 SEIU Drug List
- Assist360 Enrollment Form
- Provider Tip Sheet: Enrollment for Replacement Products
- Rxoutlook® 1St Quarter 2021
- Specialty Drug List 04-09-12
- Meta-Analysis for Efficacy of Romiplostim for Treatment Of
- Romiplostim and Eltrombopag for Immune Thrombocytopenia: Methods for Indirect Comparison
- Nplate® (Romiplostim) – New Indication
- Specialty Pharmacy Medication List
- Pdf; Alefacept, Ginfo/DRUG INFO 14 4 2000 INN-84
- CDER List of Licensed Biological Products with (1
- Publication Agenda CHMP 07-10 December 2020
- List of Drugs Requiring Prior Authorization by La Capitale
- A Review of Romiplostim Mechanism of Action and Clinical Applicability
- STEM CELL BIOLOGY and HEMATOPOIETIC GROWTH FACTORS David J
- 5.01.566 Pharmacotherapy of Thrombocytopenia
- Request Guidelines Submitting Your Request